CancerIQ Platform More than Doubles Number of Patients Identified as Eligible for MRI Surveillance to Detect Cancer Earlier
Riverside Healthcare presented data at the NCBC Conference, where CancerIQ also announced new partnership agreements with Cordata, MRS, and PenRad
CHICAGO, March 17, 2019 /PRNewswire-PRWeb/ -- Riverside Healthcare and Cancer IQ, Inc. presented the results of a 24-month study of a high-risk program to screen and identify women at elevated risk for hereditary cancer in the mammography setting at the National Consortium of Breast Centers 29th annual Interdisciplinary Breast Center Conference today in Las Vegas. The study was selected as an Abstract Award Winner and chosen for oral presentation at the meeting.
Implementing CancerIQ's evidence-based risk assessment tools at Riverside Healthcare led to 2.5 times as many patients being identified as high risk and more than doubled the number of patients eligible for ongoing MRI surveillance, per NCCN guidelines, to detect cancer earlier. The retrospective study compared the results of a paper screening system used from September 2016 to August 2017 with the results of using the CancerIQ Screening Toolkit™ from September 2017 to August 2018. A similar number of patients were screened over the two years.
According to national guidelines, approximately 2.7 million people in the US are estimated to be at elevated hereditary risk for breast and ovarian cancer. Unfortunately, the majority are not identified due to challenges in the screening process.
"CancerIQ's technology helped us overcome barriers to identifying women at increased risk for cancer by simplifying the screening process, providing immediate determination of patient risk, and reducing stress levels for both our patients and our mammography technicians," said Julie Sieling, CNP, MSN, APN, NP-C, creator of the Riverside Healthcare Screening and Risk Assessment Program and the lead author of the study.
"We're passionate about offering patients a better understanding of their risk for developing hereditary cancers because it allows them to be more empowered in their healthcare decisions," added Kathleen Curiel, Director of Radiology Services at Riverside Healthcare.
CancerIQ is collaborating with the National Comprehensive Cancer Network® (NCCN®) to reference the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Screening and Diagnosis and NCCN Guidelines® for Colorectal Cancer Screening within the CancerIQ Screening Toolkit™. The NCCN Guidelines are the recognized standard for clinical policy in cancer care and are the most thorough and frequently updated clinical practice guidelines available in any area of medicine.
In similar fashion, Sharp HealthCare in San Diego also increased annual breast MRI screenings for high-risk patients after partnering with CancerIQ. After implementing CancerIQ into their clinical workflow, Sharp HealthCare maximized their productivity and increased their patient volume by over 40 percent; streamlined their referrals and improved referring physician satisfaction; and increased their downstream revenue potential.
To further streamline risk assessment and workflow, CancerIQ also announced new partnerships with Cordata Healthcare Innovations, MRS Systems, Inc., and PenRad Technologies, Inc.
"The results achieved by Riverside Healthcare and other partners who have implemented our technology continue to validate our approach to making genetic information more widely available to patients and providers so they can act sooner to mitigate cancer risk," said Feyi Olopade Ayodele, CEO of CancerIQ. "We are excited to partner with Cordata, MRS, and PenRad to provide even more patients access to quality genetic screening and counseling, as well as the follow-up testing they need in order to preempt or prevent cancer."
About CancerIQ
CancerIQ's technology enables hospitals to identify, evaluate and manage entire patient populations based on individual genetic risk factors. By analyzing family history, running predictive risk models and automating NCCN guidelines, CancerIQ empowers community-based providers with the genetic expertise to prevent cancer or catch it early. The platform has been rapidly adopted by some of the top health systems in the country and fully integrates with genetics laboratories, EHRs, and specialty software vendors to streamline workflow, guide clinician decision making, achieve cost savings, and – most importantly – improve patient outcomes. Learn more about how CancerIQ is scaling the use of genetic testing to predict, preempt and prevent disease at Canceriq.com.
About Riverside Healthcare
Riverside Medical Center is located in Kankakee, Illinois, and is part of Riverside Healthcare, a fully-integrated healthcare system serving the needs of patients throughout five Illinois counties including Kankakee, Iroquois, Livingston, Will, Grundy and parts of Western Indiana. Riverside Medical Center is a 312-bed Level II Trauma hospital that provides a full scope of inpatient and outpatient care. Offering award-winning programs in heart care, cancer care, neurosurgery, orthopedics and a reputation for nursing excellence has placed Riverside as a leader nationally and locally. Riverside is the area's only Magnet® Recognized hospital and ranks among the top 5 percent of hospitals nationwide for clinical performance. The healthcare system has earned the Watson Health 100 Top Hospitals® award nine times and is a multi-year recipient of Healthgrades Distinguished Hospital for Clinical Excellence Award. Riverside Medical Group includes more than 140 primary and specialty care providers that deliver care at sites throughout the region. For more information visit riversidehealthcare.org.
SOURCE PRWeb House E-Commerce
Share this article